Latest market price
14.31
-0.03-0.21%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.21 | Insider Own | 47.40% | Shs Outstand | 18.48M | Perf Week | 2.51% |
| Market Cap | 264.40M | Forward P/E | 8.08 | EPS next Y | 1.77 | Insider Trans | -0.37% | Shs Float | 9.92M | Perf Month | -0.42% |
| Enterprise Value | 95.40M | PEG | — | EPS next Q | 0.11 | Short Float | 7.85% | Perf Quarter | -37.35% | ||
| Income | -22.00M | P/S | 0.29 | EPS this Y | -56.32% | Short Ratio | 3.91 | Perf Half Y | -26.05% | ||
| Sales | 913.00M | P/B | 0.46 | EPS next Y | 132.89% | ROA | -3.15% | Short Interest | 779.03K | Perf YTD | -27.10% |
| Book/sh | 30.90 | P/C | 1.56 | EPS next 5Y | — | ROE | -4.16% | 52W High | 23.59 -39.34% | Perf Year | -27.03% |
| Cash/sh | 9.15 | P/FCF | 16.52 | EPS past 3/5Y | -45.54% -37.03% | ROIC | -23.84% | 52W Low | 12.57 13.84% | Perf 3Y | -68.51% |
| Dividend Est. | — | EV/EBITDA | 2.33 | Sales past 3/5Y | -2.53% -4.01% | Gross Margin | 77.45% | Volatility | 3.47% 4.05% | Perf 5Y | -85.67% |
| Dividend TTM | — | EV/Sales | 0.10 | EPS Y/Y TTM | -167.06% | Oper. Margin | 1.35% | ATR (14) | 0.59 | Perf 10Y | -80.52% |
| Dividend Ex-Date | — | Quick Ratio | 1.84 | Sales Y/Y TTM | 1.44% | Profit Margin | -2.43% | RSI (14) | 45.29 | Recom | 2.88 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.66 | EPS Q/Q | -109.46% | SMA20 | -2.64% | Beta | 0.65 | Target Price | 35.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | -5.51% | SMA50 | -1.67% | Rel Volume | 0.66 | Prev Close | 14.34 |
| Employees | 1,570 | LT Debt/Eq | 0.00 | Earnings | Nov 03 | SMA200 | -20.97% | Avg Volume | 212.57K | Price | 14.31 |
| IPO Date | Apr 04, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -116.28% -4.99% | Net Debt/EBITDA | -4.12 | Volume | 141,020 | Change | -0.21% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-24 | Reiterated | DA Davidson | Neutral | $38 → $35 |
| Jul-25-24 | Reiterated | DA Davidson | Neutral | $46 → $38 |
| May-07-24 | Reiterated | DA Davidson | Neutral | $46 |
| Jul-07-22 | Downgrade | Jefferies | Hold → Underperform | |
| Apr-27-22 | Reiterated | DA Davidson | Neutral | |
| Jul-03-19 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| Apr-23-18 | Downgrade | Pivotal Research | Buy → Hold | |
| Jan-24-18 | Downgrade | Sidoti & Co. | Buy → Neutral | |
| May-03-17 | Upgrade | Pivotal Research | Hold → Buy | |
| May-01-17 | Downgrade | Pivotal Research | Buy → Hold |
Latest News· Times ET
Oct-12-26
Oct-12-2604:30PM
Oct-07-26
Oct-07-2607:06AM
Oct-01-26
Oct-01-2607:07AM
Sep-21-26
Sep-14-26
Sep-11-26
Sep-03-26
Sep-03-2607:08AM
Sep-01-26
Sep-01-2607:06AM
Aug-28-26
Aug-27-26
Aug-17-26
Aug-09-26
09:04AM
USANA Health Sciences Q2 Earnings Call Highlightsmarketbeat.com
Aug-05-26
Aug-05-2603:27PM
03:20PM
Company
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Core nutritional and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It offers Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company was founded in 1992 and is headquartered in Salt Lake City, Utah.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 1/3/2026 | FY 2024 12/28/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 913 | 925 | 855 | 921 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 205 | 201 | 176 | 189 | — | — | — | — | — | |
| Gross Profit | 708 | 724 | 679 | 732 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 334 | 337 | 601 | 627 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 12 | 11 | — | — | — | — | — | |
| Other Operating Expense | 362 | 337 | -1 | 1 | — | — | — | — | — | |
| Operating Income | 12 | 51 | 66 | 93 | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -9 | -8 | 10 | 10 | — | — | — | — | — | |
| Net Income Before Taxes | 2 | 42 | 76 | 102 | — | — | — | — | — | |
| Income Taxes | 32 | 30 | 34 | 39 | — | — | — | — | — | |
| Consolidated Net Income | -22 | 11 | 42 | 64 | — | — | — | — | — | |
| Net Income From Continuing Operations | -30 | 11 | 42 | 64 | — | — | — | — | — | |
| Net Income | -22 | 11 | 42 | 64 | — | — | — | — | — | |
| EPS (Recurring) | -1.21 | 0.58 | 2.20 | 3.33 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.21 | 0.58 | 2.20 | 3.33 | — | — | — | — | — | |
| EPS (Diluted) | -1.21 | 0.58 | 2.19 | 3.30 | — | — | — | — | — | |
| EBITDA | 41 | 82 | 99 | 123 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 33.52 | 16.30 | 16.24 | — | — | — | — | — | |
| Price To Sales Ratio | 0.28 | 0.40 | 0.79 | 1.11 | — | — | — | — | — | |
| Gross Margin | 77.55 | 78.27 | 79.42 | 79.48 | — | — | — | — | — | |
| Operating Margin | 1.31 | 5.51 | 7.72 | 10.10 | — | — | — | — | — | |
| Net Margin | -2.41 | 1.19 | 4.91 | 6.95 | — | — | — | — | — | |
| Shares Outstanding | 18 | 19 | 19 | 19 | — | — | — | — | — | |
| Market Capitalization | 258 | 369 | 678 | 1,018 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| WOOD TIMOTHY E | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 13,469 | Oct 23 |
| FULLER GILBERT A | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 3,264 | Oct 23 |
| Nixon J Scott | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 13,077 | Oct 23 |
| Pelosi Peggie | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 7,693 | Oct 23 |
| Fleming John Turman | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 7,494 | Oct 23 |
| Winssinger Frederic J | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 11,365 | Oct 23 |
| Ding Xia | Director | Oct 22 '26 | Option Exercise | 0.00 | 1,632 | 0 | 9,910 | Oct 23 |
| Benedict Peter | CHIEF INFORMATION OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 598 | 0 | 598 | Jul 27 |
| Armstrong Kathryn Michelle | CHIEF SCIENTIFIC OFFICER | Jul 25 '26 | Option Exercise | 0.00 | 1,166 | 0 | 3,989 | Jul 27 |
| Winssinger Frederic J | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 9,733 | Jul 27 |
| WOOD TIMOTHY E | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 12,245 | Jul 27 |
| Nixon J Scott | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 11,445 | Jul 27 |
| FULLER GILBERT A | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 1,632 | Jul 27 |
| Pelosi Peggie | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 6,996 | Jul 27 |
| Fleming John Turman | Director | Jul 23 '26 | Option Exercise | 0.00 | 1,632 | 0 | 5,862 | Jul 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.